User login
The first day of the Food and Drug Administration’s hearing on Avastin (bevacizumab) came to an end with a question-and-answer session between FDA officials and representatives from Genentech, the maker of the drug.
Earlier in the day, the Center for Drug Evaluation and Research (CDER) presented its position and stood by its proposal to withdraw approval for the breast cancer indication for Avastin.
The first day of the Food and Drug Administration’s hearing on Avastin (bevacizumab) came to an end with a question-and-answer session between FDA officials and representatives from Genentech, the maker of the drug.
Earlier in the day, the Center for Drug Evaluation and Research (CDER) presented its position and stood by its proposal to withdraw approval for the breast cancer indication for Avastin.
The first day of the Food and Drug Administration’s hearing on Avastin (bevacizumab) came to an end with a question-and-answer session between FDA officials and representatives from Genentech, the maker of the drug.
Earlier in the day, the Center for Drug Evaluation and Research (CDER) presented its position and stood by its proposal to withdraw approval for the breast cancer indication for Avastin.